Terminology Service < Semantic Lookup Platform

All terms in BAO

Label	Id	Description
inhibitor	CHEBI_35222
protein denaturant	CHEBI_50533
application	CHEBI_33232
application	BAO_0110001
mongolian spot	DOID_4702
skin disease	DOID_37	[An integumentary system disease that is located_in skin.]
antidote to paracetamol poisoning	CHEBI_74529
antidote	CHEBI_50247
antidote to curare poisoning	CHEBI_74530
fold change	BAO_0000193	[It is the ratio of biological activity in the presence of an exogenous substance to that in its absence. The fold change is useful when comparing test compounds evaluated across multiple functional assays because varying levels of efficacy can be observed amongst the different or same reference agonists.]
response endpoint	BAO_0000181	[Reporting the extent / magnitude of the perturbation (induced by the perturbagen) such as percent inhibition. Response-type endpoints would typically be obtained from a single concentration perturbagen measurement.]
Ki	BAO_0000192	[Ki is the equilibrium inhibitor dissociation constant, the concentration of the competing inhibitor that results in binding to half the enzymes sites at equilibrium in the absence of substrate or other competitors. The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([L]/Kd)) relates IC50 to Ki under conditions of competitive binding; Kd equilibrium dissociation constant of the (labeled) ligand, [L] ligand concentration. The Cheng and Prusoff equation: Ki - (IC50) / ( 1+ ([S]/Km)) relates IC50 to Ki under conditions of competitive inhibition; Ki equilibrium enzyme inhibitor dissociation constant; Km Michaelis-Menton constant, [S] substrate concentration.]
concentration response endpoint	BAO_0002162
binding constant	BAO_0000587	[This endpoint type describes the bonding affinity between two molecules at equilibrium, e.g., drug-receptor interaction.]
IC80	BAO_0000191	[The effective concentration of an inhibitor, which produces 80% of the maximum possible response for that inhibitor.]
IC50	BAO_0000190	[The effective concentration of an inhibitor, which produces 50% of the maximum possible response for that inhibitor.]
AC50	BAO_0000186	[The effective concentration of a perturbagen, which produces 50% of the maximal possible response, which could mean either activation (EC50) or inhibition (IC50) for that perturbagen.]
peritonitis	DOID_8283	[A gastrointestinal system disease that involves inflammation of the peritoneum resulting from perforation of the gastrointestinal tract, which produces immediate chemical inflammation followed shortly by infection from intestinal organisms. Peritonitis can also result from appendicitis, diverticulitis, strangulating intestinal obstruction, pancreatitis, pelvic inflammatory disease, mesenteric ischemia, intraperitoneal blood, barium, or peritoneo-systemic shunts, drains, and dialysis catheters in the peritoneal cavity. The symptoms include abdominal pain and tenderness, fever, fluid in the abdomen, nausea, vomiting and low urine output.]
gastrointestinal system disease	DOID_77	[A disease of anatomical entity that is located_in the gastrointestinal tract.]
GI50	BAO_0000189	[The effective concentration of a growth inhibitor, which produces 50% of the maximum possible response for that inhibitor. GI50 is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, where Tz is absorbance at time zero, Ti is absorbance in the presence of test drug, and C is absorbance in the control (untreated cells). As a measure of viable or proliferating cells, different researchers measure different parameters, namely, protein content (by sulforhodamine B staining followed by absorbance measurement), mitochondrial dehydrogenase activity (by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide, known as MTT staining followed by absorbance measurement), expression of proliferation associated antigens (by immunostaining for Ki-67), and ATP content (by using CellTiter-Glo reagent (Promega) followed by luminescence measurement).]